What were the results of the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study?
The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) study found that, compared to atenolol, losartan treatment led to a significant reduction in the incidence of cardiovascular morbidity and mortality. The results of this study, which were published in the Lancet in 2002, showed that losartan reduced the risk of cardiovascular death by 15% and the risk of stroke by 24%. Additionally, losartan was found to be superior to atenolol in reducing the risk of combined cardiovascular events, such as heart attacks, stroke, and heart failure. These findings suggest that losartan may be an effective treatment for reducing the risk of cardiovascular disease in patients with hypertension. 